As with other drugs, Ingrezza (valbenazine) can cause side effects, such as drowsiness and parkinsonism. If you are unable to tolerate Ingrezza’s side effects, talk with your doctor or ...

The company is best known for its drug, Ingrezza. Ingrezza treats tardive dyskinesia and chorea associated with Huntington's disease. Both are movement disorders. But in the fourth quarter ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

And people taking Ingrezza can stay on most mental health ... cost less or minimize bothersome side effects botulinum toxin injections (Botox), which can relax the muscle contractions causing ...

Q4 revenue was $627.7 million, slightly below the $629 million estimate. Ingrezza remains the main revenue driver, with a 23% increase in quarterly sales to $615 million. Neurocrine Biosciences ...

The firm sees potential upside for Neurocrine shares with multiple commercial products, including Ingrezza and Crenessity, and late stage programs in schizophrenia and depression, the analyst ...

The payer coverage changes suggests gradually increasing stringency around Ingrezza utilization, which may help explain Q4 weakness and the company’s disappointing FY25 guidance, the analyst ...